Free Trial

Dr. Reddy's Laboratories Q3 2025 Earnings Report

Dr. Reddy's Laboratories logo
$12.56 -0.69 (-5.17%)
As of 11:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Dr. Reddy's Laboratories EPS Results

Actual EPS
$0.20
Consensus EPS
$0.19
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Dr. Reddy's Laboratories Revenue Results

Actual Revenue
N/A
Expected Revenue
$975.71 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dr. Reddy's Laboratories Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Remove Ads

Dr. Reddy's Laboratories Earnings Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More Dr. Reddy's Laboratories Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dr. Reddy's Laboratories? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dr. Reddy's Laboratories and other key companies, straight to your email.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories (NYSE:RDY), together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

View Dr. Reddy's Laboratories Profile

More Earnings Resources from MarketBeat